Advertisement

Analytical and Bioanalytical Chemistry

, Volume 405, Issue 30, pp 9617–9623 | Cite as

Circulating miRNAs: a new generation of anti-doping biomarkers

  • Nicolas LeuenbergerEmail author
  • Neil Robinson
  • Martial Saugy
Trends
Part of the following topical collections:
  1. Anti-doping Analysis

Abstract

MicroRNAs (miRNAs) are small non-coding RNAs that regulate a variety of biological processes. Cell-free miRNAs detected in blood plasma are used as specific and sensitive markers of physiological processes and some diseases. Circulating miRNAs are highly stable in body fluids, for example plasma. Therefore, profiles of circulating miRNAs have been investigated for potential use as novel, non-invasive anti-doping biomarkers. This review describes the biological mechanisms underlying the variation of circulating miRNAs, revealing that they have great potential as a new class of biomarker for detection of doping substances. The latest developments in extraction and profiling technology, and the technical design of experiments useful for anti-doping, are also discussed. Longitudinal measurements of circulating miRNAs in the context of the athlete biological passport are proposed as an efficient strategy for the use of these new markers. The review also emphasizes potential challenges for the translation of circulating miRNAs from research into practical anti-doping applications.

Keywords

Doping Circulating microRNAs Biomarkers Athlete biological passport 

Notes

Acknowledgements

We acknowledge Yorck Olaf Schumacher and Torben Pottgiesser for critical reading of the manuscript. Our research on circulating miRNAs was supported by Partnership for Clean Competition (PCC), the World Anti-Doping Agency, and Exiqon grant program.

References

  1. 1.
    Fabian MR, Sonenberg N, Filipowicz W (2010) Regulation of mRNA translation and stability by microRNAs. Annu Rev Biochem 79:351–379CrossRefGoogle Scholar
  2. 2.
  3. 3.
    Pritchard CC, Cheng HH, Tewari M (2012) MicroRNA profiling: approaches and considerations. Nat Rev Genet 13:358–369CrossRefGoogle Scholar
  4. 4.
    Weber JA, Baxter DH, Zhang S, Huang DY, Huang KH et al (2010) The microRNA spectrum in 12 body fluids. Clin Chem 56:1733–1741CrossRefGoogle Scholar
  5. 5.
    Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK et al (2008) Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A 105:10513–10518CrossRefGoogle Scholar
  6. 6.
    Arroyo JD, Chevillet JR, Kroh EM, Ruf IK, Pritchard CC et al (2011) Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. Proc Natl Acad Sci U S A 108:5003–5008CrossRefGoogle Scholar
  7. 7.
    Turchinovich A, Weiz L, Langheinz A, Burwinkel B (2011) Characterization of extracellular circulating microRNA. Nucleic Acids Res 39:7223–7233CrossRefGoogle Scholar
  8. 8.
    Turchinovich A, Burwinkel B (2012) Distinct AGO1 and AGO2 associated miRNA profiles in human cells and blood plasma. RNA Biol 9:1066–1075CrossRefGoogle Scholar
  9. 9.
    Turchinovich A, Weiz L, Burwinkel B (2012) Extracellular miRNAs: the mystery of their origin and function. Trends Biochem Sci 37:460–465CrossRefGoogle Scholar
  10. 10.
    Bala S, Petrasek J, Mundkur S, Catalano D, Levin I et al (2012) Circulating microRNAs in exosomes indicate hepatocyte injury and inflammation in alcoholic, drug-induced, and inflammatory liver diseases. Hepatology 56:1946–1957CrossRefGoogle Scholar
  11. 11.
    Li C, Pei F, Zhu X, Duan DD, Zeng C (2012) Circulating microRNAs as novel and sensitive biomarkers of acute myocardial Infarction. Clin Biochem 45:727–732CrossRefGoogle Scholar
  12. 12.
    Starkey Lewis PJ, Dear J, Platt V, Simpson KJ, Craig DG et al (2011) Circulating microRNAs as potential markers of human drug-induced liver injury. Hepatology 54:1767–1776CrossRefGoogle Scholar
  13. 13.
    Williams Z, Ben-Dov IZ, Elias R, Mihailovic A, Brown M et al (2013) Comprehensive profiling of circulating microRNA via small RNA sequencing of cDNA libraries reveals biomarker potential and limitations. Proc Natl Acad Sci U S A 110:4255–4260CrossRefGoogle Scholar
  14. 14.
    Ma R, Jiang T, Kang X (2012) Circulating microRNAs in cancer: origin, function and application. J Exp Clin Cancer Res 31:38CrossRefGoogle Scholar
  15. 15.
    Pritchard CC, Kroh E, Wood B, Arroyo JD, Dougherty KJ et al (2012) Blood cell origin of circulating microRNAs: a cautionary note for cancer biomarker studies. Cancer Prev Res (Phila) 5:492–497CrossRefGoogle Scholar
  16. 16.
    Duttagupta R, Jiang R, Gollub J, Getts RC, Jones KW (2011) Impact of cellular miRNAs on circulating miRNA biomarker signatures. PLoS One 6:e20769CrossRefGoogle Scholar
  17. 17.
    Laterza OF, Lim L, Garrett-Engele PW, Vlasakova K, Muniappa N et al (2009) Plasma MicroRNAs as sensitive and specific biomarkers of tissue injury. Clin Chem 55:1977–1983CrossRefGoogle Scholar
  18. 18.
    Redova M, Sana J, Slaby O (2013) Circulating miRNAs as new blood-based biomarkers for solid cancers. Future Oncol 9:387–402CrossRefGoogle Scholar
  19. 19.
    Lawrie CH, Gal S, Dunlop HM, Pushkaran B, Liggins AP et al (2008) Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. Br J Haematol 141:672–675CrossRefGoogle Scholar
  20. 20.
    Shen J, Stass SA, Jiang F (2013) MicroRNAs as potential biomarkers in human solid tumors. Cancer Lett 329:125–136CrossRefGoogle Scholar
  21. 21.
    Brase JC, Wuttig D, Kuner R, Sultmann H (2010) Serum microRNAs as non-invasive biomarkers for cancer. Mol Cancer 9:306CrossRefGoogle Scholar
  22. 22.
    Shen J, Liu Z, Todd NW, Zhang H, Liao J et al (2011) Diagnosis of lung cancer in individuals with solitary pulmonary nodules by plasma microRNA biomarkers. BMC Cancer 11:374CrossRefGoogle Scholar
  23. 23.
    Kuwabara Y, Ono K, Horie T, Nishi H, Nagao K et al (2011) Increased microRNA-1 and microRNA-133a levels in serum of patients with cardiovascular disease indicate myocardial damage. Circ Cardiovasc Genet 4:446–454CrossRefGoogle Scholar
  24. 24.
    Leuenberger N, Jan N, Pradervand S, Robinson N, Saugy M (2011) Circulating microRNAs as long-term biomarkers for the detection of erythropoiesis-stimulating agent abuse. Drug Test Anal 3:771–776CrossRefGoogle Scholar
  25. 25.
    Kelly BN, Haverstick DM, Lee JK, Thorner MO, Vance ML, et al. (2013) Circulating microRNA as a biomarker of human growth hormone administration to patients. Drug Test Anal, Mar 12 doi: 101002/dta1469 [Epub ahead of print]Google Scholar
  26. 26.
    Leuenberger N, Schumacher YO, Pradervand S, Sander T, Saugy M et al (2013) Circulating microRNAs as Biomarkers for Detection of Autologous Blood Transfusion. PLoS One 8(6):e66309CrossRefGoogle Scholar
  27. 27.
    McDonald JS, Milosevic D, Reddi HV, Grebe SK, Algeciras-Schimnich A (2011) Analysis of Circulating MicroRNA: Preanalytical and Analytical Challenges. Clin Chem 57(6):833–840CrossRefGoogle Scholar
  28. 28.
    Blondal T, Jensby Nielsen S, Baker A, Andreasen D, Mouritzen P et al (2013) Assessing sample and miRNA profile quality in serum and plasma or other biofluids. Methods 59:S1–6CrossRefGoogle Scholar
  29. 29.
    Andreasen D, Fog JU, Biggs W, Salomon J, Dahslveen IK et al (2010) Improved microRNA quantification in total RNA from clinical samples. Methods 50:S6–9CrossRefGoogle Scholar
  30. 30.
    Jacobsen N, Andreasen D, Mouritzen P (2011) Profiling microRNAs by real-time PCR. Methods Mol Biol 732:39–54CrossRefGoogle Scholar
  31. 31.
    Pottgiesser T, Sottas PE, Echteler T, Robinson N, Umhau M et al (2011) Detection of autologous blood doping with adaptively evaluated biomarkers of doping: a longitudinal blinded study. Transfusion 51:1707–1715CrossRefGoogle Scholar
  32. 32.
    Sottas PE, Vernec A (2012) Current implementation and future of the Athlete Biological Passport. Bioanalysis 4:1645–1652CrossRefGoogle Scholar
  33. 33.
    Schumacher YO, Saugy M, Pottgiesser T, Robinson N (2012) Detection of EPO doping and blood doping: the haematological module of the Athlete Biological Passport. Drug Test Anal 4:846–853CrossRefGoogle Scholar
  34. 34.
    Robinson N, Sottas PE, Pottgiesser T, Schumacher YO, Saugy M (2011) Stability and robustness of blood variables in an antidoping context. Int J Lab Hematol 33:146–153CrossRefGoogle Scholar
  35. 35.
    Grasedieck S, Sorrentino A, Langer C, Buske C, Dohner H et al (2013) Circulating microRNAs in hematological diseases: principles, challenges and perspectives. Blood :Apr 2 [Epub ahead of print]Google Scholar
  36. 36.
    Mraz M, Malinova K, Mayer J, Pospisilova S (2009) MicroRNA isolation and stability in stored RNA samples. Biochem Biophys Res Commun 390:1–4CrossRefGoogle Scholar
  37. 37.
    Schumacher YO, Wenning M, Robinson N, Sottas PE, Ruecker G et al (2010) Diurnal and exercise-related variability of haemoglobin and reticulocytes in athletes. Int J Sports Med 31:225–230CrossRefGoogle Scholar
  38. 38.
    Schumacher YO, Sahm D, Baumstark MW, Pottgiesser T (2010) Reticulocytes in athletes: Longitudinal aspects and the influence of long- and short-term exercise. Drug Test Anal 2:469–474CrossRefGoogle Scholar
  39. 39.
    Baggish AL, Hale A, Weiner RB, Lewis GD, Systrom D et al (2011) Dynamic regulation of circulating microRNA during acute exhaustive exercise and sustained aerobic exercise training. J Physiol 589:3983–3994CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2013

Authors and Affiliations

  • Nicolas Leuenberger
    • 1
    Email author
  • Neil Robinson
    • 1
  • Martial Saugy
    • 1
  1. 1.Swiss Laboratory for Doping Analyses, University Center of Legal Medicine, Centre Hospitalier Universitaire Vaudois and University of LausanneLausanneSwitzerland

Personalised recommendations